60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
February 20, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
August 30, 2023 07:32 ET | Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
Candida + auris
Hardy Diagnostics Releases HardyCHROM™ Candida + auris
October 20, 2021 06:00 ET | Hardy Diagnostics
SANTA MARIA, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Hardy Diagnostics is pleased to announce its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective...
Ondine Biomedical Inc. to Present Candida auris Program Results at the 5th International Conference on Prevention & Infection Control (ICPIC, 2019, Geneva)
September 06, 2019 11:37 ET | Ondine Biomedical Inc.
Vancouver, Canada, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc. announces presentation of data demonstrating high levels of efficacy of its Photodisinfection program against Candida...
PositiveID to Exhibi
PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the American Association of Critical-Care Nurses Exposition May 22-24
May 21, 2018 08:00 ET | PositiveID Corporation
DELRAY BEACH, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that...